Hashemi Mohammad, Amininia Sahadi, Ebrahimi Mahboubeh, Hashemi Seyed Mehdi, Yousefi Javad, Eskandari-Nasab Ebrahim, Taheri Mohsen, Ghavami Saeid
Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran,
Med Oncol. 2014 Aug;31(8):111. doi: 10.1007/s12032-014-0111-8. Epub 2014 Jul 8.
Lysosome associated protein transmembrane 4beta (LAPTM4B) contribute to the risk of numerous cancers. The present study focused on the possible association between LAPTM4B polymorphism and the risk of breast cancer (BC) in an Iranian population in southeast Iran. This case control study includes 311 BC patients and 225 healthy women. Genomic DNA was extracted from the whole blood by salting out method and LAPTM4B genotype was investigated using polymerase chain reaction. Our findings showed that LAPTM4B genotype was not associated with the risk of BC in any inheritance model tested. The minor allele frequency in case and control group was 0.297 and 0.278, respectively. The minor allele (LAPTM4B2) was not associated with BC risk in comparison with LAPTM4B1 allele (odds ratio 1.10, 95 % confidence intervals 0.84-1.44, p = 0.495). Moreover, LAPTM4B polymorphism was not associated with clinical and pathological characteristics in the patient group. In conclusion, the findings of our study suggested that the polymorphism of LAPTM4B gene was not associated with susceptibility to BC and clinicopathological characteristics in an Iranian population.
溶酶体相关蛋白跨膜4β（LAPTM4B）与多种癌症的风险相关。本研究聚焦于伊朗东南部人群中LAPTM4B基因多态性与乳腺癌（BC）风险之间的可能关联。这项病例对照研究纳入了311例BC患者和225名健康女性。采用盐析法从全血中提取基因组DNA，并使用聚合酶链反应研究LAPTM4B基因型。我们的研究结果表明，在任何测试的遗传模型中，LAPTM4B基因型均与BC风险无关。病例组和对照组的次要等位基因频率分别为0.297和0.278。与LAPTM4B1等位基因相比，次要等位基因（LAPTM4B2）与BC风险无关（优势比1.10，95%置信区间0.84 - 1.44，p = 0.495）。此外，LAPTM4B基因多态性与患者组的临床和病理特征无关。总之，我们的研究结果表明，在伊朗人群中，LAPTM4B基因的多态性与BC易感性及临床病理特征无关。
